Grivas Petros, Kiedrowski Lesli A, Sonpavde Guru P, Gupta Sumati V, Thomas Roby A, Gourdin Theodore S, Hardin Aaron I, Hamann Kimberly M, Faltas Bishoy M, Vogelzang Nicholas J
University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.
Medical Affairs, Guardant Health, Redwood City, CA, USA.
Bladder Cancer. 2021 May 25;7(2):143-148. doi: 10.3233/BLC-201517. eCollection 2021.
Detecting genomic alterations (GAs) in advanced urothelial carcinoma (aUC) can expand treatment options by identifying candidates for targeted therapies. Erdafitinib is FDA-approved for patients with platinum-refractory aUC with activating mutation or fusion in . We explored the prevalence and spectrum of GAs identified with plasma cfDNA NGS testing (Guardant360) in 997 patients with aUC. GAs were detected in 201 patients (20%) with characterized activating GAs in 141 (14%). Our results indicate the Guardant360-based GA detection rate is similar to those described from previous studies employing tumor tissue testing, suggesting that plasma-based cfDNA NGS may non-invasively identify candidates for anti-FGFR targeted therapies.
检测晚期尿路上皮癌（aUC）中的基因组改变（GA）可通过识别靶向治疗候选者来扩大治疗选择。厄达替尼已获美国食品药品监督管理局（FDA）批准，用于治疗具有特定激活突变或融合的铂类难治性aUC患者。我们通过血浆游离DNA（cfDNA）二代测序检测（Guardant360），对997例aUC患者中GA的发生率和谱进行了探索。在201例患者（20%）中检测到GA，其中141例（14%）具有特征性激活GA。我们的结果表明，基于Guardant360的GA检测率与先前采用肿瘤组织检测的研究中所描述的相似，这表明基于血浆的cfDNA二代测序可能能够非侵入性地识别抗成纤维细胞生长因子受体（FGFR）靶向治疗的候选者。
